Physician profile
Venkat Subramaniam
NPI 1437681186
$7,957.07
in general payments reported to CMS, 2019-2025
20 companies · $2,788 in 2025
The $2,788 reported for 2025 was more than what 96% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $382 · 2023: $1,305 · 2024: $3,482 · 2025: $2,788.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,355 · Travel and Lodging: $2,819 · Education: $400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,355.29 |
| Travel and Lodging | $2,819.49 |
| Education | $400.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $2,052.73 | 2024-2025 | Pascal, Sapien 3 Ultra Resilia, Evoque |
| Boston Scientific Corporation | $1,590.36 | 2022-2025 | Accolade Sr, Emblem Mri S-Icd, S-Icd System Magnet |
| Medtronic, INC. | $1,558.48 | 2022-2024 | Corevalve Evolut R, Onyx Frontier, Azure Xt Dr Mri Surescan |
| Abiomed | $917.61 | 2023-2025 | Impella |
| Abbott Laboratories | $515.06 | 2023-2025 | Merlin@Home, Mitraclip, Fortify Assura |
| Amgen INC. | $318.83 | 2022-2025 | Repatha, Repatha |
| Penumbra, INC. | $143.00 | 2025 | Indigo System |
| Biotronik INC. | $140.92 | 2022-2023 | Acticor 7 Vr-T Dx |
| Novo Nordisk INC | $140.87 | 2023-2025 | Ozempic |
| E.R. Squibb & Sons, L.L.C. | $134.34 | 2022-2024 | Camzyos |
| Janssen Pharmaceuticals, INC | $110.32 | 2024 | Xarelto |
| Shockwave Medical, INC | $77.40 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Pfizer INC. | $71.33 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.94 | 2023 | Jardiance |
| Stryker Corporation | $30.74 | 2025 | Flowtriever |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $29.87 | 2024 | |
| Lexicon Pharmaceuticals, INC. | $28.08 | 2024 | |
| Livanova USA, INC. | $22.06 | 2022 | |
| Merck Sharp & Dohme LLC | $19.14 | 2025 | Verquvo |
| Janssen Scientific Affairs, LLC | $15.99 | 2024 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Venkat Subramaniam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.